摘要
目的探讨注射用重组人白介素-11(rh IL-11)治疗吉西他滨化疗所致血小板减少的临床效果。方法选取2014年10月至2016年12月间武汉大学人民医院收治的112例吉西他滨化疗所致血小板减少患者,根据患者意愿(是否同意使用rh IL-11)将其分入观察组和对照组,观察组67例,对照组45例。观察组患者采用rh IL-11治疗,对照组患者采用氨肽素治疗,比较两组患者治疗前及治疗7d后的血小板(PLT)水平、达标例数和达标时间,比较两组患者的临床疗效和不良反应。结果观察组与对照组PLT达标率分别为94.0%和75.6%,达标时间分别为(6.12±1.27)d和(9.65±2.86)d,差异均有统计学意义(均P<0.05);观察组患者总有效率为94.0%,高于对照组患者的75.6%,差异有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论 rh IL-11治疗吉西他滨化疗所致血小板减少有较好的临床疗效,血小板达标所需时间较短,效率较高,优于一般性升血小板药物。
Objective To explore the clinical efficacy of recombinant human interleukin-11（ rh IL-11） for thrombocytopenia induced by gemcitabine chemotherapy. Methods A total of 112 patients with thrombocytopenia induced by gemcitabine chemotherapy were selected at People＇s Hospital of Wuhan University from October 2014 to December 2016 According to patients＇ preference,these patients were divided into an observation group（ 67 patients） and a control group（ 45 patients）. Patients in the observation group were given rh IL-11 and patients in the control group were given amino-peptide. Levels of platelet（ PLT） level before the treatment and at 7 d after the treatment were compared. Response rate and time as well as clinical efficacy and adverse reactions were also compared. Results Response rate and time was 94. 0% and（ 6. 12 ± 1. 27） d for the observation group and 75. 6% and（ 9. 65 ± 2. 86） d for the control group,respectively（ all P〈0. 05）. The overall efficacy rate was 94. 0% for the observation group which was higher than 75. 6% of the control group（ P〈0. 05）. There was no significant difference in the incidence of adverse reactions between the two groups（ P〈0. 05）. Conclusion rh IL-11 shows good efficacy for thrombocytopenia induced by gemcitabine chemotherapy with short response time and is superior to general platelet drugs.
出处
《中国肿瘤临床与康复》
2017年第12期1422-1424,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
基金
国家自然科学基金面上项目(81372407)
武汉大学2016年度自主科研项目(2042016kf0088)
关键词
血小板减少
化疗
重组人白介素-11
Thrombocytopenia
Chemotherapy
Recombinant human interleukin-11
